Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Placing

12 Nov 2009 07:00

RNS Number : 3824C
Futura Medical PLC
12 November 2009
 



For immediate release 

12 November 2009

Futura Medical plc

("Futura" or "the Company")

Placing

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce a Placing by Nomura Code Securities Limited in which gross proceeds of £1.46 million are being raised through the issue of 4,864,471 new ordinary shares of 0.2 pence each in Futura ("Ordinary Shares"), to new and existing institutional and other investors at a price of 30 pence per share The Placing represents approximately 7.8% of the Company's issued share capital.

The net proceeds of the fundraising will be used to provide additional working capital, to support the regulatory approval of CSD500, to progress the Company's developmental projects, as well as to evaluate some early stage research leads. Further it is expected a strengthened balance sheet will assist in the Company's out-licensing negotiations with pharmaceutical and other partners. 

The Ordinary Shares will rank pari passu with the existing ordinary shares of the Company. Application has been made to the London Stock Exchange and it is anticipated that trading of the Ordinary Shares will commence on AIM at 8:00am on 18 November 2009. 

Futura's total issued shared capital following the admission of the Ordinary Shares will be 67,483,311. The total number of voting rights in the Company will be 67,483,311.

James Barder, Futura's Chief Executive, said: "We are pleased with the support of new and existing investors in this Placing, which will allow us to progress our exciting pipeline of products and give us the ability to capture more of their long term value. We continue to manage our costs carefully and intend to exploit our low cost business model to progress those projects that we believe have significant upside. Having a strengthened balance sheet will undoubtedly be of assistance in our current out-licensing discussions."

For any further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

mail to: james.barder@futuramedical.co.uk

www.futuramedical.co.uk 

Nomura Code Securities Limited 

Charles Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

For media enquiries please contact: 

Buchanan Communications

Mark Court / Stasa Filiplic / Jennie Spivey

Tel: +44 (0) 20 7466 5000

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEKFLFFKFBFFBQ
Date   Source Headline
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 202111:06 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
15th Dec 20202:00 pmRNSPrice Monitoring Extension
15th Dec 20209:05 amRNSSecond Price Monitoring Extn
15th Dec 20209:00 amRNSPrice Monitoring Extension
8th Dec 20207:00 amRNSFutura provides US regulatory & commercial update
1st Dec 20207:00 amRNSBlock Listing Six Monthly Return
22nd Oct 20207:00 amRNSFutura provides regulatory and commercial update
21st Sep 20203:12 pmRNSDirector/PDMR Shareholding
16th Sep 20207:00 amRNSInterim Results for Six Months ended 30 June 2020
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
17th Aug 20207:00 amRNSNotice of Results
10th Aug 20207:00 amRNSFutura receives positive QMS Audit Opinion
4th Aug 20207:00 amRNSFutura update on CBD100 1st Stage Development Work
24th Jul 20204:40 pmRNSSecond Price Monitoring Extn
24th Jul 20204:35 pmRNSPrice Monitoring Extension
14th Jul 20207:00 amRNSFutura Medical provides EU & US regulatory update
10th Jul 20204:31 pmRNSBlock listing Interim Review - Replacement
24th Jun 20204:22 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.